产品资料

sRANKL total (OPGL)

如果您对该产品感兴趣的话,可以
产品名称: sRANKL total (OPGL)
产品型号: DE1930042
产品展商: 原装进口
产品文档: 无相关文档

简单介绍

sRANKL total (OPGL)


sRANKL total (OPGL)  的详细介绍
sRANKL total (OPGL)

产品名称:sRANKL total ELISA
产    地:Demeditec 
产品货号:DE1930042
产品规格:96 Tests
产品说明:
Special remarks: This testkit measures total soluble RANKL (free and bound) in serum and plasma samples. sRANKL, receptor activator of nuclear factor (NF)-kB ligand (also: osteoprotegerin ligand, OPGL), is a part of the TNF superfamily with high similarity to other members of that protein species (SwissProt Nr. 014788).
Three isoforms are produced by alternate splicing, two type II membrane proteins (ISOFORM 1, 317 AA, and ISOFORM 3, 270 AA), and a secreted molecule (ISOFORM 2, 244 AA). ISOFORM 1 is identical to previously reported RANKL and possesses intracellular, transmembrane, and extracellular domains; ISOFORM 2 does not have the intracellular and transmembrane domains, and ISOFORM 3 does not have the intracellular domain. A soluble form arises by proteolytic processing from membrane isoforms.
Although all forms are bioactive, the membrane-bound proteins seem to be the homeostatic forms, while the production of soluble RANKL signals pathological conditions.
RANKL, RANK, and osteoprotegerin (OPG) have been identified as the key molecular regulation system for bone remodelling. RANKL is the main stimulatory factor for the formation of mature osteoclasts and is essential for their survival. Therefore, an increase in RANKL expression leads to bone resorption and bone loss. RANKL is produced by osteoblastic lineage cells and activated T lymphocytes. It activates its specific receptor RANK, which is located on osteoclasts and dendritic cells. The effects of RANKL are counteracted by OPG, which is secreted by various tissues and acts as an endogenous soluble receptor antagonist.
Imbalances of the RANKL/OPG system have been related to the pathogenesis of Paget’s disease, benign and malignant bone tumors, postmenopausal osteoporosis, rheumatoid arthritis, bone metastases and hypercalcemia. Several studies using animal models have shown that restoring the RANKL/OPG balance (e.g. by administering OPG) reduces the severity of these disorders.
Indication
- Postmenopausal and senile osteoporosis
- Diseases with locally increased bone resorption activity
- Paget´s disease
- Periodontal disease
- Cardiovascular disease, arterial calcification
- Inflammatory diseases
- Immunological disorders
- Arthritis
- Oncology
上海玉博生物技术有限公司在为生命科学领域提供丰富的产品与信息资源方面处于国内**地位,公司提供的产品涵盖了二十多个国家近五十万种产品,而且产品的数量与信息在不断的增长和更新,公司提供的产品能够使生命科学工作者加快对生物化学,分子生物学,细胞生物学以及蛋白质组学研究的认知,以及分子诊断和临床医学领域的应用。

产品留言
标题
联系人
联系电话
内容
验证码
点击换一张
注:1.可以使用快捷键Alt+S或Ctrl+Enter发送信息!
2.如有必要,请您留下您的详细联系方式!
使用指南 付款方式 客户关怀 **与保密 法律帮助 服务条款 监察中心信箱
分享到:

沪公网安备 31011002002623号